Company Profile

Apollomics Inc (AKA: CBT Pharmaceuticals Inc)
Profile last edited on: 10/30/2023      CAGE: 7UGU7      UEI: M2APMF87NPR8

Business Identifier: Immuno-oncology: discovery and development of oncology combination therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

989 East Hillsdale Boulevard Suite 220
Foster City, CA 94404
   (650) 209-4055
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

SBIR involved only since 2018, CBT Pharmaceutical was provided seed funding by its parent firm Crown Bioscience International Inc. with the spin off involved in devveloping immuno-oncology therapies and having development activities with four projects in its preclinical pipeline. Renamed Appollomics in January 2019, the firm is focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. The firm's pipeline comprises of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NIH $160,000
Project Title: Combination of Checkpoint Inhibitors

Key People / Management

  Sanjeev Redkar -- Founder, President and CEO

  Guo-Liang Yu -- Co-Founder and CEO

  Wilson W Cheung -- Chief Financial Officer

  Gavin S Choy -- Chief Operating Officer and Executive Vice President

  Uwe Peukert -- Head of Business Development and Clinical Development

Company News

There are no news available.